News Releases 2023
May 11, 2023
Chugai's FJ2 Project, designed and constructed by JGC JAPAN CORPORATION, was selected as Winner of the Innovation Category of the Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
Chugai Pharmaceutical Co., Ltd. ("Chugai"), for which JGC JAPAN CORPORATION ("JGC") was in charge of design and construction, has been selected as Winner of the Innovation Category of the Facility of the Year Awards (FOYA)*1 by ISPE. The announcement by ISPE was made on May 9, 2023 on the occasion of the 2023 ISPE Europe Annual Conference 2023.
FOYA is an international competition to select pharmaceutical-related facilities with outstanding innovative technologies in five categories: Innovation, Operations, Supply Chain, Pharma 4.0TM, and Social Impact. After a rigorous screening process, Chugai and JGC's FJ2 project was selected as Winner of the Innovation category. In October of this year, one project will be announced as the Overall Winner from among the six Category Winners, including the FJ2 project.
The FJ2 Project called for the design and construction of a small and mid-size molecule APIs manufacturing facility (Building No. 48) at the Fujieda plant of Chugai Pharma Manufacturing Co., Ltd., a group company of Chugai. Basic design began in February 2018, construction commenced in November 2019, and completion was achieved in August 2022 following commissioning and qualification. Building No. 48 comprises facilities for the manufacturing of mid-size molecule APIs such as peptides, as well as facilities for the manufacturing of small molecule APIs, and auxiliary facilities.
The facility adopts JGC's proprietary next-generation containment technology, CONPAStainment®*2, to ensure worker safety from exposure to highly potency compounds, enabling the manufacturing of highly active APIs which have been difficult to manufacture until now.
In the selection of the Innovation Category winner, we believe that our following five leading technologies unique to this project were highly evaluated.
(1) Adoption of CONPAStainment®, a world-class advanced containment technology
(2) Multi-purpose mid-size molecule APIs facility
(3) Advanced "Cleanability" APIs manufacturing equipment
(4) Adoption of natural refrigerants to reduce CFC emissions
(5) Introduction of High-Performance Projects™ concept for construction project execution
JGC has been engaged in pharmaceutical and life science engineering for nearly half a century as "JGC Pharmaceutical Engineering, creating new value through our ability to propose and execute solutions." And today, responding to the dramatic technological advances in pharmaceutical engineering, JGC continues to execute projects fully meeting the needs of our clients from quality and timeliness perspectives, by providing optimal solutions drawing on the company's extensive track record of over 650 projects and the accumulated expertise of more than 400 dedicated pharmaceutical engineers.
About the FJ2 Project:
| Building Name |
Building No. 48 and Auxiliary Facilities |
|---|---|
| Structure |
Steel-structure, four-story building, seismic isolation structure. |
| Total floor area | Approximately 6,079m2 (Building No. 48) |
| Type of facility | Pharmaceutical plant (small and mid-size molecule APIs) |
| Completion | August 2022 |
※１：Facility of the Year Awards (FOYA)
Established in 2005, The Facility of the Year Awards (FOYA) recognize state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery. The FOYA program provides a platform for the pharmaceutical science and manufacturing industry to showcase its accomplishments in facility design, construction, and operation, while sharing the development of new applications of technology and cutting-edge approaches. Visit https://ispe.org/facility-year-awards for more information.
※２：About CONPAStainment®
Chemical hazards containment technology based on JGC's patent. Combined with our proprietary upper transfer rail system, the technology can be easily and safely moved between equipment. CONPAStainment® has high containment performance, achieving the world's highest OEL (Occupational Exposure Limits) ≤ 0.05 μg/m3.
※３：High-Performance Projects™
A program offered by JMJ Associates to enhance team engagement and maximize organizational performance by fostering trust and open communication, and empowering stakeholders to collaborate effectively towards a shared vison.
Chugai Fujieda No.48 Bldg.
Facility adopting CONPAStainment® 